| ALK | |
|---|---|
| Protein Name | Anaplastic Lymphoma Kinase |
| Gene | ALK |
| UniProt ID | Q9UHB8 |
| Protein Family | Insulin receptor family |
| Molecular Weight | ~200 kDa (full-length) |
| Expression | Brain (neurons), lymphoid tissue |
| Function | Receptor tyrosine kinase, neural development |
ALK (Anaplastic Lymphoma Kinase) is a receptor tyrosine kinase encoded by the ALK gene. Originally discovered in anaplastic large cell lymphoma (ALCL), ALK is expressed primarily in the nervous system during development and in certain neuronal populations in adults. ALK plays crucial roles in neural development, synaptic plasticity, and has been implicated in neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and ALS [1].
ALK is a type I transmembrane receptor:
ALK can be activated by:
In cancer, ALK can be constitutively activated through:
During nervous system development, ALK is highly expressed:
In adult brains, ALK expression persists in:
ALK signaling provides neurotrophic support:
In Alzheimer's disease, ALK may play complex roles:
Evidence for ALK-mediated neuroprotection:
ALK-targeted approaches for AD:
In Parkinson's disease, ALK signaling may:
ALK has been implicated in:
PTN is a neurotrophic factor that activates ALK:
Another ALK ligand:
ALK activation may provide therapeutic benefits:
Cancer-approved ALK inhibitors include:
Potential CNS applications require CNS-penetrant compounds.
ALK is a receptor tyrosine kinase expressed in the nervous system with important roles in neural development, synaptic plasticity, and neuronal survival. While best known for its oncogenic role in lymphomas, ALK provides essential neurotrophic support to neurons and may be relevant to neurodegenerative diseases including Alzheimer's and Parkinson's disease. Targeting ALK signaling represents a potential therapeutic strategy for enhancing neuronal survival in these conditions.